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We are honored to contribute to this Festschrift celebrating Professor Morris L. Eaton, one of the 
preeminent theoretical statisticians of our time. We pay tribute to him -- for his distinguished and 
illustrious career at the University of Minnesota, for his innovative and highly influential body of 
research, and for his dedicated and selfless service to the statistics profession.  
Readers of this volume will be familiar with Joe Eaton’s pioneering and fundamental research in 
many areas of theoretical statistics. They may be less familiar with his work on methodological 
problems of particular importance to statisticians in the pharmaceutical industry, and we would like to 
take this opportunity to highlight some of this work.  He has made important contributions to our 
understanding of statistical issues in both early and late stage drug development; these will have 
lasting impact.  They include research in very diverse areas (the following list is not intended to be 
exhaustive):  dissolution profile testing, where the aim is to show through in vitro testing that the 
dissolution properties of (for example) a new formulation of an approved drug are  statistically 
“similar” to the existing formulation, a necessary step in obtaining a bio-waiver for in vivo testing  
(Eaton et al, 2003); the statistical evaluation of a decision rule in a regulatory guidance for assessing 
whether a new drug in development prolongs the length of the QT interval (an ECG measurement) 
which, because QT prolongation is a safety signal for potential cardiac problems, can lead to the 
development of a compound being halted (Eaton et al, 2006a); the construction and evaluation of 
multivariate Bayesian predictive distributions and reference (or tolerance) regions  for assessing a 
vector of laboratory values, providing a novel approach  to monitoring the safety of a drug in clinical 
trials (Eaton et al, 2006b); the testing of multiple co-primary endpoints, where a new drug must 
demonstrate efficacy on a number of variables in order to gain regulatory approval  (Eaton and 
Muirhead, 2007); and large-sample properties of “proper Bayesian” and “hybrid classical-Bayesian” 
approaches to sample sizing of clinical trials (Eaton et al, 2012, and used in the current paper). On 
behalf of the pharmaceutical statistical community, we thank Joe for his willingness to be involved in 
industry problems and for his many important contributions.  
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Abstract 
This paper explores an approach to Bayesian sample size determination in clinical trials. The 
approach falls into the category of what is often called "proper Bayesian", in that it does not mix 
frequentist concepts with Bayesian ones. A criterion for a “successful trial” is defined in terms of a 
posterior probability, its probability is assessed using the marginal distribution of the data, and this 
probability forms the basis for choosing sample sizes.  We illustrate with a standard problem in 
clinical trials, that of establishing superiority of a new drug over a control.  
 
1. Introduction 
Sample size determination plays an important role in the design aspect of studies in many fields, 
and especially in the planning of clinical trials. Although applicable to other situations (such as 
equivalence trials and non-inferiority trials), our focus here is on superiority trials, where the aim is to 
establish that a new experimental treatment is more efficacious than (superior to) a control, such as 
placebo or an existing treatment. The frequentist approach is well known. For a given test of the null 
hypothesis of no difference between the two treatments, we specify a significance level (or size) ,  
the magnitude *  (say) of the magnitude of the treatment effect   considered “clinically meaningful”, 
and 1 , , the desired power at *.  We then determine a sample size so that the  test of level   will 
reject the null hypothesis with probability 1   if, in fact,  the “true” treatment effect is *.  Frequentist 
sample size formulas are available in  commonly occurring situations, whether based on standard tests 
themselves or on lengths of confidence intervals. (See, for example, Joseph and Bélisle (1997) and 
Whitehead et al (2008).) These formulas generally involve “guesses” (estimates) of the values of 
nuisance parameters, such as unknown variances. These estimates, which are usually obtained from 
prior studies, or from published studies on the same (or a similar) drug, are treated as “correct” in 
frequentist sample sizing (although, of course, sensitivity analyses are routinely carried out to see how 
sample sizes are affected by the choice of the values of nuisance parameters). The fact that the 
estimates obtained from prior studies and from expert opinions sometimes underestimate the 
variability actually observed in a new trial can lead to an underpowered study.  In addition, what *
should actually represent remains open to debate. The regulatory guideline ICH E9 (which 
immediately follows introductory remarks by Lewis (1999)) recommends that * may be based either 
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on “a judgment concerning the minimal effect which has clinical relevance in the management of 
patients or on a judgment concerning the anticipated effect of the new treatment, where this is larger.” 
That the anticipated effect size is often optimistically overstated may also lead to an underpowered 
study. For further discussion on these matters, see e.g. Grouin et al (2007) and O’Hagan et al (2005). 
Because of the uncertainty involved in the specification of both * and nuisance parameters, it is 
natural to incorporate Bayesian concepts into the sample size determination process. Possible 
approaches have been classified by Spielgelhalter et al (2004) as “hybrid classical-Bayesian”, 
“decision-theoretic Bayesian”, and “proper Bayesian”. The most common example of the hybrid 
classical-Bayesian approach involves specifying a prior distribution for unknown model parameters, 
and then averaging the (frequentist) power function with respect to this prior to obtain an “average 
power”, also called “predictive power” (see Whitehead et al (2008)) and “assurance”  (see O'Hagan et 
al (2005)). The basic idea is to pre-specify a value for the average power and use this as the basis for 
sample sizing.  (This pre-specified value must be chosen with care; it does not seem to be widely 
appreciated that, as the sample size increases, the average power is bounded above by the prior 
probability that the new treatment is better than the control.)  A frequentist analysis will then follow, 
after the trial data has been collected. In the decision-theoretic Bayesian approach, “sample size is 
based on maximization of a utility function, formulated to reflect concerns involving mainly measures 
of cost and benefit” (Whitehead et al (2008)). Because of the difficulties involved in specifying utility 
functions in practice and because “misspecification of utilities can lead to seriously sub-optimal 
designs”, Whitehead et al (2008) conclude that “implementation (of decision-theoretic Bayesian 
approaches) in clinical trial design has been and probably will remain limited”. We agree with this 
assessment. 
In a “proper Bayesian” approach to sample size determination, it is assumed that a Bayesian 
analysis will be performed at the end of the trial, and that the analysis will generally be based on 
whatever criterion (in terms of a posterior distribution) has been specified at the sample size 
determination stage. Whether or not this is actually done however (and, as is pointed out in O’Hagan 
et al (2005), regulatory agencies have been slow to adopt formal guidelines encouraging Bayesian 
analyses in Phase III drug confirmatory trials), the use of Bayesian concepts at the design stage leads 
to increased understanding of how sample size is affected by the specification of prior distributions 
which incorporate prior knowledge. An approach proposed by Whitehead et al (2008) for exploratory 
clinical trials falls into the “proper Bayesian” category, as do methods based on credible intervals, 
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such as average coverage and average length (see e.g. Joseph and Bélisle (1997) and M'Lan et al 
(2008), and the references therein). It should also be pointed out that proposals have been made to 
utilize two different priors for the different stages of design and analysis (see e.g. Brutti et al (2008) 
and O’Hagan and Stevens (2001)). In the latter paper, the “analysis prior” is essentially non-
informative, so that the analysis more closely resembles a standard frequentist one. We do not pursue 
this approach here, although it is straightforward to implement. 
This paper is structured as follows. In Section 2 we describe a “proper Bayesian” approach to 
sample size determination that seems intuitively appealing; it is based on choosing a sample size 
which gives a pre-specified “probability of a successful trial”, where the probability is calculated using 
the marginal distribution of the data. Section 3 is concerned with specific examples and applications in 
a common clinical trial setting, that of comparing the means of two normally distributed samples. 
 
2. The “Probability of a Successful Trial” Criterion 
Assume that, in a clinical trial, we will collect data 1, , nX X  on a total of n subjects, where 
   1, ,
n
nX X X has a joint distribution that depends on a parameter   , where   is a subset of a 
multidimensional Euclidean space.  The variable iX  being measured or calculated for final analysis is 
often referred to as the “primary endpoint” of the trial. This is usually 1-dimensional, but may be 
multivariate if there are two or more primary endpoints. Let 0 and 1 be two disjoint, non-empty 
subsets of ,  with 0 1 .     (In a classical hypothesis testing framework, these subsets correspond 
to null and alternative hypotheses.) We are interested in concluding that 1.     
Let   denote a prior distribution for , and denote by   | nn x   the posterior distribution of 
given the observed data   1
n
n
x x x( ) , , .   In the notation being used here, distributions refer to 
probability measures. (In the examples in Section 3, these distributions will have probability density 
functions.) Thus, for example,  1   and 
  1 | nn x     are respectively the prior and posterior 
probabilities that 1.   
Suppose that, at the analysis stage (that is, after the data ( )nx has been observed), we call a clinical 
trial a success if the posterior probability that 1   is greater than or equal to a specified threshold 
 0,1 ;  that is, if 
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  1 | .nn x                                                                               (1) 
At the design stage, since we haven't yet collected the trial data, we cannot evaluate the left side of (1). 
We can, however, assess the inequality (1) using the marginal (or unconditional) distribution, ( )nXP  
(say), of ( )nX , obtained from the joint distribution of  
n
X (given  ) and the prior  by integrating out 
 . (In the Bayesian sample size determination literature, this distribution has also been called the 
“predictive distribution”; see, e.g. Joseph and Bélisle (1977) and Brutti et al (2008).) We can ask: 
What is the probability, according to the marginal distribution   ,n
X
P  that the trial will be a success? 
Formally, this involves calculating the quantity 
( )
( )( ) ( ),n
n
nX
n P X E                                                              (2) 
where nE  denotes the set of all samples 
( )nx  which lead to a successful trial, namely 
 ( ) ( )1; ( | ) .n nn nE x x                                                            (3) 
We will refer to ( )n  in (2) as the probability of a successful trial and abbreviate it as PST. (It has 
also been called “expected Bayesian power” by Spielgelhalter et al (2004), and “predictive 
probability” by Brutti et al (2008).) The basic idea now is to choose a sample size n  for which the 
PST ( )n  is “large enough”, in the sense that it exceeds a specified threshold. As we note below, 
there is a limitation on the size of this threshold. It is clear that, for fixed n,  n increases as   in (1) 
decreases; that is, the lower the threshold for defining a successful trial, the greater the chance of 
obtaining a sample leading to one. 
Although we have emphasized the dependence in (2) of ( )n  on n, it of course also depends on 
any hyperparameters in the prior  , as well as the subset 1  deemed appropriate and the choice of the 
threshold  . In practical situations, we would choose   to be “large”, with the choice influenced by 
the specification of 1,  and by the type of trial. In the examples in Section 3, 1 will correspond to a 
classical alternative hypothesis, and we will take 1 ,   where  is a standard significance level. 
(The choice of significance level is influenced by the type of trial – it is generally taken to be smaller 
for a confirmatory (Phase III) trial than for an exploratory or earlier phase trial.)  As previously noted, 
the PST increases as   decreases, and this will be illustrated in Section 3. 
How large can the PST in (2) be? This raises the non-trivial question of how ( )n  behaves as for 
large n. In the examples in Section 3, for the parameter values considered, ( )n  is an increasing 
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function of n, for all n. In the first example in Section 3 (two normal samples with unknown means 
and known common variance), it is straightforward to show that 
                                                              
1lim ( ) ( );
n
n 

                                                                   (4) 
that is, no matter what value of  0,1  is chosen in (1) to define a successful trial, as n , the 
PST ( )n  approaches the prior probability that 1.   The limiting result (4) has been obtained by 
Brutti et al (2008) in the case of a single normal sample with unknown mean and known variance.  It is 
established in Eaton et al (2012) that (4) holds much more generally, with the proof hinging on 
consistency of the posterior distribution. (For a discussion of Bayesian consistency, see Ghosh and 
Ramamoorthi (2003)). Thus, even with an infinite sample size (where we would learn the “true” value 
of  ), the PST cannot exceed the prior probability that 1.   Because of this, it may be more 
informative, when choosing a sample size, to focus attention on the “normalized PST index” 
 
 
 
*
1
,
n
n





                                                             (5) 
for which
*lim ( ) 1,
n
n

  so that  * n represents the proportion of the maximum value of the PST 
explained by the sample size n.  We do this in the examples in the next section. 
 
3. Examples 
Throughout this section, we consider a normal model for comparing the means of two populations, 
corresponding to experimental treatment E and control C. We base our notation loosely on that used 
by Whitehead et al (2008). We have independent samples of sizes En  and Cn  from each population, so 
that the model (conditional on parameters) is 
   1 11 1, , ~ , , , , ~ , .E Cn E n EX X iid N Y Y iid N   
                                      (6) 
We assume that the precision   is the same in both populations.  Let E Cn n n   denote the total 
sample size, and let E CR n n be the allocation ratio. In terms of n and R, the two sample sizes are 
   / 1 , / 1 .E Cn nR R n n R    Typically we fix a value of R, and then the two group sample sizes 
follow from the choice of n. (In the illustrations below, we will always take R=1, so that there are 
equal sample sizes in the two groups.) The parameter of interest here is the treatment effect 
,E C     and positive values of   are assumed to favor the experimental treatment E over the 
control C. We base our definition of a “successful trial” (see (1)) on the posterior probability that 
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0.   (It is straightforward to modify this to *   (for example) if this seems more appropriate in a 
particular situation.) 
3.1  Known precision, conjugate prior: When  is known, a standard conjugate prior specifies that  
the two means E and C are independent, with  
 
 
 
 
0 0
0 0
1 1
~ , , ~ , .E E C C
E C
N N
n n
   
 
  
  
   
   
                                                (7) 
Here        
0 0 0 0
, , ,E C E Cn n   are specified, and the superscript (0) is used to indicate a quantities in (or 
calculated from quantities in) prior distributions. (In what follows, the superscript (1) will similarly 
indicate a quantity in a posterior distribution.) The  
0
'sn multiplying the precision play the role of 
“pseudo observations”, and allow us to weight prior information differently in the groups E and C. We 
might, for example have much more information about the control group C from previous trials or 
historical data,  in which case we might choose  
0
Cn  to be large in comparison with 
 0
En . The aim in 
such a situation would be to allocate more subjects to group E (allocation ratio 1R ). 
With the Bayesian model specified by (6) and (7), the posterior distribution of E C     depends 
only on the trial results through the observed sample means x and ,y  and is  
 
 
1
1
1
, ~ , ,x y N
D
 

 
 
 
                                                               (8) 
where the posterior mean  
1
  is the difference between the posterior means of E and ,C  namely 
         1 1 1 1, ,E Cx y                                                                 (9) 
 
with  
 
 
 
        
 
 
        
1 0 0 1 0
1
1 0 0 1 0
1
1
, ,
1
, ,
E E E E E E E
E
C C C C C C C
C
n n x n n n
n
n n y n n n
n
 
 
   
   
                                           (10) 
and  
1
D  in (8) is 
 
  
   
   
1 1
1
1 1
.E C
E C
n n
D
n n


                                                              (11) 
From (1), we call the trial a success if the posterior probability that 0  exceeds a specified threshold 
.  This condition is equivalent to  
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    
1 1
,D z                                                               (12) 
where z  denotes the  quantile of the  0,1N distribution. Then the PST is (see (2))   
    
 
1
1
,
z
n P
D

 

  
  
  
                                                            (13) 
where the probability in (13) is calculated using the marginal distribution of    1 , .X Y  This 
distribution is  2, ,N  with mean and variance given by 
    
       
0 0 2
0 1 0 1
, .CEE C
E E C C
nn
n n n n
  
 
                                               (14) 
Consequently, 
  
 1
1
.
z
n
D


 
  
     
  
  
                                                 (15) 
(Note that this depends on the prior means only through their difference . ) Since the prior probability 
that 0   is  
    00 ,P D     
 
                                                      (16) 
where  
 
   
   
0 0
0
0 0
,E C
E C
n n
D
n n


                                                              (17) 
the normalized PST index (see(5)) is 
  
 
 
1
*
0
1
.
z
D
n
D

 


  
    
  
  
   
 
                                                       (18) 
Example 3.1.1: The “International Restless Legs Syndrome Study Group Rating Scale” (IRLS) is used 
in clinical trials that attempt to show that a drug is efficacious in treating “Restless Legs Syndrome” 
(RLS). The IRLS is a clinician-administered 10-item questionnaire used to assess the severity of RLS.  
The overall score ranges from 0 to 40, with lower scores reflecting lower severity and better quality of 
life. We consider a randomized trial aimed at comparing a drug group with a placebo group, and take 
as the endpoint the difference between the IRLS score at baseline and at the end of the trial. If the drug 
is efficacious, we would expect to see positive values of this difference in the drug group. 
For the purpose of illustration here, assume the standard deviation (SD) of the endpoint in both 
populations is known to be 8. (This is about equal to the average SD observed in Allen et al (2010), a 
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published RLS study.) In a frequentist approach, assume a difference in mean scores (drug vs. 
placebo) of 4 is “clinically meaningful”. In a confirmatory Phase III trial, a test of “no difference 
between drug and placebo” is usually a 2-sided, 0.05-level test (even when the hope is to conclude that 
drug is better than placebo); consequently we will focus here on a 1-sided 0.025-level test. A standard 
normal-based calculation shows that, in order to have 80% power at * 4,  we need 64 subjects in 
each group, for a total sample size of 128. 
Figure 1 illustrates how the normalized PST index (18) behaves as a function of total sample size n 
for four different values of the difference in prior means , when 1,R   0.975  and the prior weights 
are taken to be    
0 0
2E Cn n  (in which case the prior distribution of the treatment effect   is  ,64 ).N 
As noted in Section 2, the curves all converge to 1 as the sample size increases, although this is not 
obvious from Figure 1, which only goes to 200.n   In a practical setting, we would probably choose
to reflect our prior opinion, perhaps based on previous studies, about the treatment effect. 
Alternatively, we might take it to be the “clinically meaningful” treatment effect.  If we take, for 
example, 4,  the PST converges to a maximum of  0.5  0.6915. The normalized PST index 
gives the proportion of this maximum value achieved for various sample sizes – see Table 1. We see, 
for example, that when 100n  (so there are 50 subjects in each group, the PST is 79% of its maximum 
value, and it is increasing only slowly with n. There is not much to be gained, in terms of the PST, by 
taking larger sample sizes.  Also, we noted in Section 2 that, for fixed ,  the PST increases as the 
threshold   decreases (and then, of course, a smaller sample size may be chosen) – see Figure 2. 
When the prior weights  
0
En  and 
 0
Cn  are increased (so that the prior distributions for the means are 
sharper or more informative) we expect the PST to also increase. The second set of two rows in Table 
1, with    
0 0
30,E Cn n   illustrates this. The PST values are considerably higher here than in the first set; 
the normalized PST index is 0.80 with a total sample size of 60. 
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Figure 1: Normalized PST index versus n for various values of Δ. ( 0.975    SD = 8,    
0 0
2E Cn n  ) 
 
 
 
 
 
 n 40 60 80 100 120 140 
 
   0 0
2E Cn n   
 n  0.46 0.50 0.53 0.55 0.56 0.57 
 * n  0.67 0.73 0.77 0.79 0.81 0.83 
 
   0 0
30E Cn n   
 n  0.75 0.78 0.81 0.82 0.84 0.85 
 * n  0.77 0.80 0.83 0.85 0.86 0.87 
 
Table 1: Values of the PST and the normalized PST index for two sets of values of  
0
En and 
 0
Cn when 
4.   ( 0.975  , SD = 8) 
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Figure 2: Normalized PST index versus n for various values of the threshold   ( 4,   SD = 8,    
0 0
2E Cn n  ) 
 
3.2  Known precision, mixture prior: Suppose that we are in a situation where we believe that there 
is some chance (perhaps small) that the treatment effect   is “close” to zero. This might arise, for 
example, when a prior is based on the elicitation of opinions of experts, some of whom are skeptical 
about the efficacy of a proposed new drug, whereas others are more confident. In the frequentist 
setting, when testing the null hypothesis 0,  sufficiency and translation invariance leads us to 
consider  
1
*~ , ,nU X Y N  
    
 
with * / .n E Cn n n    For the purpose of illustration, assume that the 
prior distribution for   is a mixture of two normal distributions,  100,N    and  11 1, ,N    with mixing 
probabilities  and 1 .  Then, given ,U u the posterior probability that 0   is 
       
* *
1 1
* *
0 0
0 1 ,n n
n n
u u
P u u u
   
  
   
   
        
       
                                (19) 
where 
  
 
*
0
*
0
; 0, ,n
n
u N u
f u
 

 
   
     
   
                                              (20) 
 and where 
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    
* *
0 1
1* *
0 1
; 0, 1 ; ,n n
n n
f u N u N u
   
  
   
          
             
         
                                (21) 
 
is the density function of the marginal distribution of .U  (In (20) and (21), the notation  2; ,N u  
denotes the  2,N   density function evaluated at u.) Then the PST is    ,nn P U E   where nE is 
the set of all values u of U for which the posterior probability (19) exceeds a specified value .  
Although an analytic expression for  n seems elusive, it is a straightforward matter to calculate it 
via Monte Carlo simulation, and a MATLAB program which does this is available from the authors. 
Example 3.2.1: This is a continuation of Example 3.1.1.  When   has the mixture prior described 
above, the prior mean and variance are 
        21 1
0 1
1
1 , Var 1 .E
 
      
 

                                                (22) 
 
For the purpose of illustration here, we take 0 100,     4E   , and, as in Example 3.1.1,  Var 64 . 
Given  , we can then determine the parameters 1 and 1  in the second mixture distribution 
appropriately. Figure 3 gives the graphs for the normalized PST index for various values of  . If, for 
example, we take  = 0.1 (in which case 11 14.44, 69.13 
  ), the limiting value of the PST is 0.6830. 
The normalized PST index gives the proportion of this maximum value achieved for various sample 
sizes – see Table 2. 
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Figure 3:  Normalized PST index versus n for various values of  , and 0.975.  (Each mixture has mean 4 
and SD 8.) 
 
 
 
 
n 20 40 60 80 100 120 140 
 n  0.32 0.40 0.44 0.46 0.48 0.49 0.50 
 * n  0.47 0.59 0.65 0.68 0.71 0.72 0.74 
 
Table 2: Values of the PST and the normalized PST index when 0.1.   
 
3.3  Unknown precision, conjugate prior:  We begin with the model in Section 3.1, but now assume 
that the precision   is unknown, and that its prior distribution is gamma, with specified 
hyperparameters  
0
  and  
0
 (so that      0 0/E    and      0 0 2Var /   ) . Given , the means 
E and C  are independent, with conditional prior distributions given by (7). Then the posterior 
distribution of  (see, e.g. Whitehead et al (2008)) is gamma, with parameters  
1
 and  
1
 , where 
 
            1 0 1 1 021 12 2, , , ,n x y s H                                                    (23) 
with  
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n
)
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=0.01
=0.2
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=0.5
=0.4
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    
 
 
  
 
 
  
00 2 2
0 02 2
1 1
, , 2 C CE E E C
E C
n nn n
H H x y s n s x y
n n
                                      (24) 
and 2s being the value of the (unbiased) pooled sample variance 2.S Next, define T as 
 
 
   
 
  
1 1
1
1
,
D
T

 

                                                           (25) 
where      
1 1 1
, ,D  and  
1
 are given in (9), (11), and (23). Then (see Joseph and Bélisle (1997), 
Whitehead et al (2008)) the posterior distribution of T is  1
2
.t

 We call the trial a success if 
 20 , , .P x y s    Using (25) this is equivalent to 
  
   
   1
1 1
1
1 2 ,
,
D
t
 



                                                            (26) 
where the right side of (26) denotes the  quantile of the  1
2
t

distribution. Then the PST is 
 
      
   
   
 1
1 1
1
1 2 ,
,
, ,
D
n P X Y t
X Y S  

 

 
 
  
  
                                          (27) 
 
where the probability in (27) is calculated using the marginal joint distribution of , ,X Y and 2.S  It may 
be shown that (27) depends on the prior means only through their difference .  Although it appears 
difficult to obtain an analytical expression,  n  in (27) can be calculated via simulation, by first 
conditioning on the model parameters. A MATLAB program that does this is available from the 
authors.  
Example 3.3.1: This continues Example 3.1.1. We use six precision estimates for IRLS change from 
baseline (mean 0.015 and SD of 0.0010 ) from Table 2 of Allen et al (2010) to fit a prior gamma 
distribution with  
0
243   and  
0
16200.   Figure 4 gives the normalized PST curves for various 
values of   when 0.975  and    
0 0
2E Cn n  (as in Figure 1). The mean precision here corresponds to 
a SD of about 8.16 (Example 3.1.1 assumed a known SD of 8), and the precision variability is small, 
so that the graphs in Figure 4 are very similar to those in Figure 1. 
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Figure 3.  Normalized PST index versus n for various values of .  
 
 
4. Summary 
We have described a “proper Bayesian” approach to sample size determination, and illustrated its 
use in a context of a two parallel arm clinical trial for superiority with normal data.  It is more widely 
applicable --- for example, in non-inferiority and equivalence trials, and to non-normal data (such as 
dichotomous data and time-to-event-data). In most instances, the proposed PST criterion will have to 
be calculated via simulation, and – at least in standard distributional settings – this appears to be 
reasonably straightforward.  The material in Section 3 may also be readily generalized to the multiple 
primary endpoints setting, although the number of hyperparameters that have to be specified in prior 
conjugate distributions grows rapidly as the dimension increases.   
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